Poltreg SA Sustainability Reports
Poltreg S.A. is a clinical-stage biotechnology company that develops innovative cell therapies using T-regulatory cells (TREGS). It primarily focuses on researching and manufacturing treatments for autoimmune and neuroinflammatory diseases, such as type 1 diabetes and multiple sclerosis.
Sector: Manufacturing
Country: Poland
Exchange: Warsaw Stock Exchange
LEI: 259400XSAJTERJ42VZ86
FIGI: BBG012T7Y599
2 reports from 2022 to 2025
